EZM0414 |
| Katalog-Nr.GC64900 |
EZM0414 ist ein potenter, selektiver, oral bioverfÜgbarer Inhibitor von SETD2 (IC50 = 18 nM im biochemischen SETD2-Assay; IC50 = 34 nM im zellulÄren Assay). EZM0414 kann fÜr die Erforschung des rezidivierten oder refraktÄren multiplen Myeloms und des diffusen großzelligen B-Zell-Lymphoms verwendet werden.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2411748-50-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
EZM0414 is a potent, selective, orally bioavailable inhibitor of SETD2 (IC50=18 nM in SETD2 biochemical assay; IC50=34 nM in cellular assay). EZM0414 can be used for the research of relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma[1].
[1]. Jennifer Totman, et al. Pharmacologic Inhibition of the Histone Methyltransferase SETD2 with EZM0414 As a Novel Therapeutic Strategy in Relapsed or Refractory Multiple Myeloma and Diffuse Large B-cell Lymphoma.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *